Studies based on drug-DNA interactions, especially anticancer drug-DNA interactions, are of great importance for the method development. It is thought that single-use electrodes, which give fast, cheap and reproducible results, will make a great contribution to the chip technology for the development of individual patient analysis in the future. It is known that antioxidants reduce carcinogenesis caused by oxidative stress with their radical scavenging effects. Literature shows that quercetin (QRCT) exhibits anticancer activity by preventing oxidative cell damage as an effective radical scavenger. In this study, Bendamustine (BND), an anticancer drug, which is used in different blood cancer types, was electrochemically determined and the toxicity degree was calculated by examining the interaction of the drug with DNA in the absence and presence of QRCT, which is the first examination in the literature. Limit of detection and quantification for BND was calculated as 6.0 and 20.0 μg/mL respectively by using the equation I = 0.029 × C+ 1.197, (R = 0.997). We found that QRCT prevents the interaction between BND and DNA because of its strong interaction with DNA.